SCHEMBL7064512

SCHEMBL7064512

CC(C)CC(NS(=O)(=O)c1ccc([N+](=O)[O-])cc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.64
MMP9 P14780 4/20 0.64
MMP1 P03956 3/20 0.64
MMP13 P45452 3/20 0.64
MMP3 P08254 2/20 0.64
MMP7 P09237 2/20 0.64
SLC1A3 P43003 1/20 0.56
SLC1A2 P43004 1/20 0.56
SLC1A1 P43005 1/20 0.56
KDM4E B2RXH2 3/20 0.56
CA2 P00918 4/20 0.53
CA1 P00915 3/20 0.53
MMP8 P22894 1/20 0.53
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
CYP2C9 P11712 1/20 0.52
CA12 O43570 3/20 0.51
CA9 Q16790 3/20 0.51
CA14 Q9ULX7 3/20 0.51
ALDH1A1 P00352 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5190668 1.00 MMP2 (0.64) MMP2MMP9MMP1MMP13MMP3
SCHEMBL29521449 0.87 MMP2 (0.52) MMP2MMP9MMP1MMP13MMP3
SCHEMBL7067052 0.86 MMP2 (0.58) MMP2MMP9MMP1MMP13MMP3
SCHEMBL9594962 0.85 MMP2 (0.50) MMP2MMP9MMP1MMP13MMP3
SCHEMBL7099900 0.83 SLC1A3 (0.59) MMP2MMP9MMP1MMP13MMP3
SCHEMBL11351046 0.83 MMP9 (0.71) MMP2MMP9MMP1MMP13MMP3
SCHEMBL3969625 0.83 MMP9 (0.71) MMP2MMP9MMP1MMP13MMP3
SCHEMBL7066619 0.83 MMP9 (0.71) MMP2MMP9MMP1MMP13MMP3
SCHEMBL5191083 0.83 MMP2 (0.70) MMP2MMP9MMP1MMP13MMP3
SCHEMBL6561338 0.83 MMP2 (0.70) MMP2MMP9MMP1MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US claimed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US claimed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP claimed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO claimed
US-20250289810-A1 Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments MAM-AGE S.R.L. (IT) 2025-09-18 US disclosed
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. 2023-11-09 US disclosed
WO-2023209109-A1 COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND THEIR USE AS MEDICAMENTS MAM - AGE S.R.L. (IT) 2023-11-02 WO disclosed
EP-4210738-A2 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. (US) 2023-07-19 EP disclosed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS FABP2, APC, SI MMP2 166/4885MMP9 612/4885MMP1 643/4885
US-20250289810-A1 Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments NLRP3, NLRP1, IL18 MMP2 1807/4885MMP9 1030/4885MMP1 381/4885
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 MMP2 1807/4885MMP9 1513/4885MMP1 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.